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Abstract
COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2) and has emerged as a devastating pandemic. SARS-CoV-2 not 
only causes respiratory illness but also leads to impairment of multi-organ func-
tion. Scientists are racing to evaluate a range of experimental therapeutics to target 
COVID-19 systemically. The World Health Organization (WHO) and the Center for 
Disease Control and Prevention (CDC) are accelerating global research priorities to 
mobilize innovation towards diagnostics, treatments, and vaccines against COVID-19. 
In this scenario, information about appropriate organ-specific physiologically relevant 
models is critical to generate knowledge about the pathophysiology and therapeu-
tic targeting of COVID-19. Human and animal organoids are providing a unique 
platform, demonstrating their applicability for experimental virology. This review 
provides a brief analysis of the available organoid models used to study and device 
strategies to combat COVID-19.
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1. Introduction
It is quite well-known that classical 2D cell lines and in vivo models have been 
used near universally to investigate biological mechanisms and assess novel thera-
pies across a large range of clinical problems [1]. Nevertheless, the results from 
these experiments are critically limited by a systemic lack of translational power for 
the response, efficacy, safety, and toxicity in humans despite its primary benefits in 
clinical research [2, 3]. Cell lines generically display insufficiency and inaccuracy in 
modeling the immune system, stromal components, and organ-specific functions 
after multiple passages [4]. Leaving aside animal welfare arguments, species-
specific variations in organ development and pathogenesis are a long-standing 
bottleneck due to which animal models cannot mimic a given human disease that 
is polymorphic, to begin with [5]. Therefore, to define and treat disease pathology 
seamlessly, biologists exploited the critical features of stem-cell and came up with 
three-dimensional (3-D) or organotypic cultures or organoids from human samples 
that could successfully phenocopy cell-type composition, architecture, and to some 
extent, functionality (e.g., contraction, filtration, excretion, neural activity, etc.) of 
their natural counterparts [6–8].
Organoids, a term coined for referring to ‘mini organs’, [9] are best described as 
in vitro three dimensional (3D) cellular clusters exclusively derived from healthy 
cells – like primary tissue, embryonic stem cells, or induced pluripotent stem cells 
(iPSCs) [10] or even tumor cells [11]. Since these cells are capable of self-renewal 
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and self-organization, organoids portray outstanding similarity to organ function-
ality as the tissue of origin compared to other conventional routes [2, 12]. The sole 
purpose of developing organoids is to recreate and miniaturize the multicellular 
structure of organs while retaining the 3-dimensional construct indefinitely.
It can now be commented that the development of organoid technology has 
generated a robust new methodology to zoom into the physiological events ex vivo, 
and this fact can be explained. Firstly, scientists have a wider domain of cell types to 
choose from, some of which were historically hard-to-access; secondly, organoids 
contain multiple differentiated cell types; and thirdly, organoids are genetically 
stable [13]. The intrinsic nature of this innovative near-physiological technology 
has created a paradigm shift in our understanding of basic developmental biology 
or stem cell research directed to a host-pathogen relationship in infectious diseases, 
degenerative conditions, genetic disorders, oncology, genome engineering, bio-
banking, and regenerative and personalized medicine [14, 15]. Through a complete 
visualization of spatiotemporal cellular interactions, organoid modeling reflects the 
predominant structural and functional properties of essential organs like kidneys 
[16], lungs [17–20], gut [21], brain [22], prostate [23], heart [24] and retina [25].
Human organoids are intrinsically human-derived, rapid-to-set-up, robust in 
scaling up, and ideal for genetic manipulation and personalization [26]. In simple 
terms, the organoid is an attractive strategy for clinical applications and bridges 
the gap between basic research and clinical practice. Along these lines, biomedical 
and pharmaceutical investigations on particularly relevant, rigorously designed, 
well-characterized, and controlled organotypic models will travel a long way in 
redefining fundamental discoveries, testing novel hypotheses at the 3D level and 
for the validation of critical data without sacrificing the integrity of any living 
being in the name of science. It should also be kept in mind that this technology is 
still in its infancy; much of the current hype originates from its enormous potential 
rather than a finite number of real-life scientific advancements. Hence, COVID-19 
researchers use bronchial, respiratory, liver, kidney, intestine, and brain organoids 
to study the pathogenesis of SARS-CoV-2 and virus-specific cellular reaction on 
various organ systems.
In this chapter, we aim to answer a plethora of scientific questions related to the 
situation around the SARS-CoV-2 battle in the light of organoid technology, empha-
sizing key findings in therapeutic interventions meant to prevent and cure the seri-
ous medical threats imposed by SARS-CoV-2. We will highlight the state-of-the-art 
tools and methodologies available for human organoid lines and deep-dive into the 
case studies of fantastic in vitro organ models that well-known research groups have 
employed for understanding the root cause of COVID-19 devastation.
2. Virology and organoid
It is well-known that immortalized cell lines and animal models have paved the 
way for identifying the pathobiology of obligate intracellular parasites or viruses. 
Despite their paramount role in this field, none can adequately reproduce human 
disease pathology or exactly recapitulate the homeostatic functions of a normal 
cell. Therefore, virologists have moved on from carrying out investigations on 
non-natural hosts to patient-derived organoid models to address the unmet need for 
human model systems in studying virology and its therapeutic interventions [27]. 
Organoid technology, a human-based model technique, has broadened the scope for 
studying viral infections by enhancing the translatability of results from in vitro cell 
cultures or ex vivo animal systems to a more human in vivo mimicking condition. 
Since the route of host-pathogen interactions largely varies based on virus nature 
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and its host type, including age, sex demographic profile, and genetic constitution 
of the hosts, it is crucial to have an accurate prototype of its natural host to conduct 
the experiments.
2.1 Culturing the unculturable
At almost all stages of replication, viruses associate closely with the host cell, 
and therefore the cell model used to research virus infection is crucial. Primary cells 
better represent the phenotype of healthy cells in vivo but have a short lifetime, are 
difficult to culture, and are heterogeneous and thereby renders manipulating them 
difficult. The widespread use of immortalized cell lines for culturing diverse virus 
strains is a common practice, but the induction of interferon-stimulated genes and 
other antiviral defenses is defective in many tumor-derived and artificially immor-
talized cell lines. These flaws can interfere with virus replication, particularly when 
cells are infected at lower, more physiologically important multiplicities. Moreover, 
there are some challenging cases where the virus fails to adapt in man-made culture 
conditions, like, norovirus or other enteric viruses, which remain unculturable to 
date in any kind of cell line system. Luckily for us, stem-cell-derived human intes-
tinal organoids have successfully grown and studied these viral cultures up to one 
round of infection [28]. Similarly, respiratory viruses which are challenging to grow 
in cell lines like human coronavirus HKU1, human bocavirus, and human rhinovi-
rus C could be successfully isolated from clinical specimens using Human airway 
epithelial (HAE) cultures [29–31]. These data prove that there is room for discover-
ing unknown viruses and their mechanism of infection, pathogenesis, and immune 
escape through the fine-tuning of crucial features of the organoid platform [32].
2.2 Reproducing the natural virus host environment
Viruses isolated from patient samples like feces, blood, or nasopharyngeal 
swabs infested with a particular infection, can be grown on organoids without 
any imposed mutation or adaption. These cultures will now exactly recapitulate 
the fundamental features and infectivity profiles of the natural host cell [33, 34]. 
Therefore, conclusions drawn on the various aspects of organotropism, receptor 
usage, innate immunity induction, etc., is now even more reliable than laboratory-
adapted or ATCC strains. The readouts used for post-infection analysis may differ 
in cell lines vs. organoids based on the culture environment and discussed in the 
following sections.
2.3 Provide new insights
Data from cell lines have earlier shown that the small open reading frame 
upstream of the main polyprotein ORF which is also present in the 5’UTR genomic 
region in enteroviruses, cannot be utilized for the initiation of translation [35]. 
Lulla et al. had reported for the first time that the small protein encoded by this 
uORF is crucial for virus release in human intestinal organoids [36]. The viruses 
lacking this uORF are therefore attenuated in this model. Later on, other publica-
tions on intestinal organoids have reiterated that different enteroviruses infect 
different cell types and induce an antiviral response characteristic of a particular 
cell type [37, 38].
To assess the influence of host conditions such as age and comorbidities on the 
progress and severity of viral infections, cross-interactions between co-detected 
pathogens in a single host can be studied closely with organoids. This was never 
feasible with cell lines because different viruses are often not culturable on the 
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same cell line. For example, respiratory viruses are well-known for causing asthma 
and pathologies like cystic fibrosis or chronic obstructive pulmonary disease. HAE 
infection samples collected from healthy and asthmatic donors with rhinovirus 
have shown a unique airway epithelial structure with inflammatory signaling in 
asthmatic patients [39, 40].
2.4 Utilization in fighting the SARS-CoV-2 pandemic
Multiple types of organoid models were used to study the detrimental effect of 
SARS-CoV-2 infection on human hosts and its potential therapeutic interventions 
[41]. To begin with, HAE cultures served as faithful models for the lungs where 
efficient replication occurred through the infection of ciliated cells in the airway 
[42]. Therapeutic investigations on organoid models showed the repurposed drug 
remdesivir and remdesivir–diltiazem to be functional in resisting further SARS-
CoV-2 infection [43]. Lamers et al. had proved for the first time that the human gut 
epithelium is the second major replication site of the virus [44]. Combined with the 
novel insights from other organoid research groups, it was proved that the SARS-
CoV-2 genome is detectable in feces even after the virus is absent from oropharyn-
geal swabs, which explains the outcome of intestinal infection and potential fecal 
transmission [45].
These findings were closely followed by the observation of increased efficiency 
to infect secondary tissue by the virus. In terms of relative importance, the next area 
of investigation using organoids has been establishing the neuro-invasive aspect of 
SARS-CoV-2 by using brain organoid models [46]. Epidemiological studies showed 
the direct contribution of SARS-CoV-2 infection to neurological complications 
like headaches, ischemic stroke, and encephalitis, including cranial nerve-related 
complications such as anosmia and hyposmia, and ageusia [47, 48]. Recently, 
Pellegrini et al. utilized choroid plexus organoids to demonstrate the potential viral 
tropism for choroid plexus epithelial cells that affect the epithelium [49]. Damage to 
this barrier is suspected as a possible entry route for the virus into the cerebrospinal 
fluid and the brain.
2.5 Extensive research in Zika virus pandemic
Zika virus, a mosquito-borne flavivirus, is reportedly the causative agent for the 
infection known as ZIKV. Although adult victims show mild symptoms, newborns 
are marked with microcephaly, a condition in which infants are born with an abnor-
mally small head. Being spread in over 70 countries and territories globally, [50] 
ZIKV is declared a global health emergency by WHO whereby microcephalic fetal 
tissues have shown traces of ZIKV in damaged fetal brains [51]. Due to accessibility 
challenges with live infected human fetal samples and postmortem tissues showing 
a diverse range of quality and genetic history, clinical examinations are replaced for 
good by brain organoid model studies. These focus on cellular tropism and patho-
genesis mechanisms of ZIKV in controlled settings [52].
In 2016, the first study on brain organoid models was published by Tang et al., 
where they used monolayer cultures of forebrain-specific neural progenitor cell 
(NPCs) to model ZIKV infection during human brain development [53]. These 
were the initial results towards projecting that ZIKV more efficiently infects NPCs 
layers over human pluripotent stem cells (hPSCs) or immature neurons. Infection 
of cerebral organoids and human neurospheres with ZIKV and dengue virus 2 
(DENV2) has proved that only ZIKV attenuates NPC growth, suggesting that the 
extreme aftereffect of ZIKV infection as an exceptional feature of the flavivirus 
family [54]. Later on, studies using brain organoids derived from hPSCs have also 
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led to a significant understanding of various other aspects of ZIKV infection on 
fetal brain development [52].
Due to the limited accessibility of organoid methodologies to virology research 
groups and the delay in the pace of commercialization of this technology, the 
majority of the published work so far has been a result of cross-functional col-
laborative efforts [55]. This challenge is closely followed by complications arising 
from heterogeneity inherent to the structural complexity and cell-type diversity 
in brain organoid models compared to simpler analogs such as neurospheres [56]. 
Moreover, the low-throughput nature of culturing and analyzing organoids creates 
a significant obstacle in drug screening which usually needs a high-throughput 
styled experimental protocol. We anticipate the evolution of more sophisticated 
brain organoids in the future that involves the co-culturing of endothelial cells or 
microglial cells to enhance the physiological relevance of modeling ZIKV infection 
during fetal human brain development.
2.6 Technical challenges
The classical nature of 3D organoid models was closed round structures embed-
ded in Matrigel, challenging to infect with viruses as receptors needed for infection 
are always located deep inside. This shortcoming was overcome in HAE cultures 
where cells are grown on a Transwell. Therefore, round gut organoids can be easily 
transformed into an open organoid model where they are accessible from the upper 
and lower sides simultaneously to establish the desired infection [28, 57, 58]. This 
model system is technically advantageous for infectious disease studies and drug-
testing in antimicrobial therapy.
The next significant challenge worth consideration is readouts used for analysis 
after infection. Due to the release of viral particles in a nonlytic manner, virus cul-
tures in primary cellular models do not result in plaque-like cytopathic effect (CPE) 
most of the time, for example, in the case of enterovirus A71. Huang et al. have 
shown using human intestinal organoids that are infected with enterovirus A71 that 
viral release happens through exosomes instead of a lytic process characteristic of 
a classical RD cell line [59]. This production is quantified through back titration 
or plaque assays using cell lines. The aforementioned protocol of measurement of 
the number of viral particles is a matter of concern in the case of primary cultures, 
which calls for more suitable evaluation methods.
3. COVID-19 and organoid
The severe acute respiratory syndrome coronavirus (SARS-CoV) first emerged 
in the human population in November 2002. Phylogenetic analysis of this viral 
isolate indicated that it has a zoonotic origin, and horseshoe bats (R. sinicus) seem to 
be its natural reservoir. With local travel restrictions and a wildlife trade ban, there 
were no further naturally acquired human cases of SARS in Guangdong, China. In 
late 2019, a novel coronavirus, SARS-CoV-2, again crossed the animal-to-human 
interspecies barrier to infect humans [60]. Palm civets and other mammals acted 
as their amplification hosts, which resulted in a super-transmissible form that 
could effectively spread from human to human at an unprecedented rate. This 
rapid propagation happened by the deposition of infected droplets or aerosols on 
the respiratory epithelium. This led to a pneumonia outbreak in Wuhan, China 
[61] which causes coronavirus disease-19 (COVID-19) marked by symptoms like 
fever, cough, shortness of breath, myalgia, fatigue, and sometimes gastrointestinal 
symptoms such as nausea, vomiting, and diarrhea [62]. Viral RNA was detected 
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in patients’ respiratory, stool and urine specimens. This condition can extend to 
severe lung injury and multi-organ failure, eventually leading to death in senile and 
comorbid patients.
In a few months, the virus had disseminated globally and sustained its patho-
genicity irrespective of external factors. After WHO declared this a public health 
emergency of pandemic proportions, there were several lockdowns, social distanc-
ing protocols, hygienic measures, strict travel bans, strategic medical care, and 
vaccination programs to control the obnoxity of this outbreak. Even after one year 
of a relentless pandemic situation, the world is trying hard to combat the collateral 
damage to the global economy, public health, and civil life.
Genomic analyses of SARS-CoV-2 prove ~96% identity to the bat coronavirus 
BatCoV RaTG13 and 88% identity to two other bats SARSr-CoVs [61, 63, 64]. Sharing 
multiple similarities with SARS-CoV [65], phylogenetic analysis of SARS-CoV-2 shows 
that it belongs to lineage B of the beta-coronavirus genus in the family Coronaviridae 
[63] and has a possible common host cell receptor due to similarity in the receptor-
binding domain. Animal model studies further confirmed that Angiotensin-converting 
enzyme 2 (ACE2)-dependent viral entry into cells is a critical step [66]. The evolution 
of different mutants is another concern, and quick studies can help understand the 
infectivity, pathogenesis, and targeting better. The B.1.1.7 variants in England, B.1.351 
mutant in South Africa, P.1 in Brazil, B.1.427 in California, and now B.1.617, a “double 
mutant” common in India, have caused havoc on life and the economy.
Like SARS and MERS, pathobiology of the recently emerged COVID-19 is not 
limited to the respiratory tract because the damage has been observed and confirmed 
repeatedly in multiple organs [65], albeit the lungs are the main site of the infection. 
To investigate the rationale behind the organotropism of SARS-CoV-2, we need 3D 
model systems that mimic the physiological conditions at their best. Herein, organ-
oid technology comes in as the basic framework of COVID-19 research with a much 
higher impact than animal models and cellular studies. Fortunately, the past decade 
has witnessed a revolutionary breakthrough in the generation of organoids for almost 
every human organ, including intricate systems like the heart, intestine, brain, 
and lung organoids. In the following sub-sections, we will discuss the constitution, 
contribution, limitations, and future applications of organoid technology in under-
standing the mechanism of organotropism by SARS-CoV-2 (Section 3.1-3.4), which 
influences and, in most cases, aggravates comorbid conditions in COVID-19 patients.
The first step in the pipeline of using 2D and 3D models for COVID-19 studies in 
vitro starts with tissue dissociation from different organs and is followed by stem/ 
progenitor cell isolation using popular sorting methods like fluorescence-activated 
cell sorting (FACS) and magnetic-activated cell sorting (MACS) (Figure 1). Sorted 
stem/progenitor cells are cultured in a 3D organoid culture system and subjected to 
SARS-CoV-2, which mimics the organ-specific infection. Different aspects of the 
post-infection studies like infection rate, gene expression analysis, infection mecha-
nism, immune-response, inflammatory response, and histology can be studied. The 
3D-organoid models can then be subjected to drug screening, drug repurposing, 
and vaccine development-related studies (Figure 1). Figure 1 provides a layout of 
the COVID-19 research platform.
3.1 Lung organoid
Dan et al. described an approach to synthesizing patient-specific lung tissue 
in a modular method to model relevant human lung disease, as well as for high-
throughput drug screening to detect targeted therapies [67]. The first development 
of long-term differentiated human airway organoid cultures, which can morpho-
logically and functionally simulate human airway epithelium, was done by Z. Zhou 
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et al. to predict the infectivity of influenza viruses [68]. Optimized to contain the 
four major airway epithelial cell types- ciliated, goblet, club, and basal cells, these 
organoids were exposed to two ‘pairs’ of already studied viruses. Resultantly, the 
pair of humans- infective virus replicated more robustly than the pair of matched 
viruses poorly infective in humans.
Several in vitro models, such as Vero cells, Huh7 cells, and human airway 
epithelial cells, have been used early on in the COVID-19 pandemic to isolate and 
study the SARS-CoV-2 virus. These studies took a notch up when SARS-CoV-2 was 
isolated and propagated in TMPRSS2-expressing Vero E6 cells, thereby proving the 
indispensable role of TMPRSS2 serine protease in viral replication. Nevertheless, 
these models are limited by their poor representation of the histology, physiology, 
and pathology of the events occurring in our respiratory tract [69]. Y. Han et al. 
have developed a lung organoid model of alveolar type II cells using human pluripo-
tent stem cells (hPSCs) that could be adapted for drug screens [70]. This organo-
typic culture was able to express ACE2 and are permissive to SARS-CoV-2 infection. 
High throughput screening experiments identified FDA-approved drug candidates, 
ima-tinib and mycophenolic acid, which are efficient inhibitors of SARS-CoV-2 
entry. Pre- or post-treatment with these drugs at physiologically relevant levels 
decreased SARS-CoV-2 infection of hPSC-derived lung organoids.
To test the validation of Remdesivir, a Covid-19 drug candidate, A. Mulay et 
al. successfully developed and infected differentiated air-liquid interface cultures 
of proximal airway epithelium and organoid cultures of alveolar epithelium by 
SARS-CoV-2 [71]. They displayed an epithelial cell-autonomous proinflammatory 
response that proved the relevance of this platform for studying COVID-19 patho-
biology and rapid drug screening against SARS-CoV-2.
3.2 Brain organoid
While the Coronavirus disease 2019 manifests clinically acute respiratory 
symptoms along with fever [72], a large subset of patients, especially younger 
victims, develop complete or partial olfactory dysfunction (anosmia/hyposmia) 
Figure 1. 
The COVID-19 research platform’s layout using 3D organoids. Tissue dissociation from various organs is the 
first step in the pipeline for using 2D and 3D models for Covid-19 studies in vitro. Isolated stem/progenitor cells 
by fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) cells are grown in 
3D using extracellular matrix mimetics and nourished with niche-specific culture medium. Stem/progenitor 
cells derived from various tissues self-organize into tissue-specific organoids. 3D organoid cultures are infected 
with SARS-CoV-2. Various aspects of post-infection studies can be conducted as shown.
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during the course of infection [73]. This loss in olfaction occurred without (83%) 
associated rhinorrhea or nasal congestion at a median of 0.5 days after symptom 
onset [74]. While the majority of patients recovered within a couple of weeks from 
the onset of olfactory symptoms, few continued to have refractory and disabling 
anosmia [75]. Neurological symptoms like headache, dysgeusia, confusion, seizure, 
and viral encephalitis have been reported in 36.4% of 214 COVID-19 patients in 
Wuhan, China, where 45.5% of patients had severe SARS-CoV-2 infections [47, 76]. 
Similarly, France and Germany reported neurologic findings in 84.5% (49/58) and 
36.4% (8/22) of COVID-19 patients, respectively, of which the latter studies had 
detected viral RNA in brain biopsies of patients who succumbed to the disease [77].
In 2016, D. Pamies et al. had put forward human mini-brains or BrainSpheres- 
an organotypic brain model derived from iPSC for the first time [78], comprising of 
different types of neurons, astrocytes, and oligodendrocytes. After its application 
on Zika, Dengue, HIV, and John Cunningham (JC) virus, they used this model to 
understand the extent of SARS-CoV-2 virus infection in human brain cells. Their 
results demonstrated that SARS-CoV-2 could infect and replicate in cells of neuro-
nal origin, thereby proving the critically potential neurotropism of SARS-CoV-2. In 
yet another study, the same group had shown that SARS-CoV-2 could directly infect 
and effectively damage the olfactory sensory neurons of golden Syrian hamsters 
[75]. The entry receptor of the spike protein in SARS-CoV-2, ACE2, is widely 
detected in the brain, especially in the substantia nigra, middle temporal gyrus, and 
posterior cingulate cortex [79, 80]. Interestingly, serine protease TMPRSS2 expres-
sion was undetectable in the BrainSpheres, which suggests an alternative mecha-
nism for spike (S) protein priming during viral entry. Together, these findings 
indicate that the human brain might be an extra-pulmonary target of SARS-CoV-2 
infection.
Initially, it was proposed that anosmia and ageusia happen due to infection of 
non-neuronal cells in the olfactory system [81], which was busted by reports sup-
porting the presence of viral particles in the CNS biofluid [82] and signs of neural 
damage biomarkers in the plasma of COVID-19 patients [83]. Taken together, a 
direct infection rather than a secondary immune response seems more accountable 
for neurological outcomes and predicted future neurodevelopmental disorders. 
Given that the human brain is arguably an extra-pulmonary target of SARS-CoV-2 
infection, biologists and neuroscientists also need to figure out the impact of 
SARS-CoV-2 on a prototypical developing brain. Brain organoid research or the 
BrainSphere model is also limited by the absence of microglia or brain immune cells 
since they originate from the mesoderm germ layer and invade the developing brain 
from the blood, unlike neural precursor cells [84].
3.3 Gut organoid
While most COVID-19 patients suffer from mild to severe respiratory illnesses, 
>50% of patients manifest gastrointestinal disorders with prolonged symptoms like 
diarrhea, nausea, etc., which becomes severe to fatal when left unattended [85]. 
Although the virus has been detected in the upper respiratory tract of humans, 
proving the nasopharynx as a prominent site of replication, the highest expression 
of ACE2 occurs in the brush border of intestinal enterocytes [86]. Interestingly, 
when 53% of a cohort of 73 hospitalized patients had SARS-CoV-2 RNA in stool 
specimens, viral RNA was found in rectal swabs of 23% of patients even after nega-
tive nasopharyngeal testing, which implied fecal-oral transmission route leading to 
gastrointestinal infection or vice-versa [87, 88]. Of note, viral nucleoprotein-posi-
tive cells were found in the gastrointestinal epithelial cells from biopsy specimens 
[89] and pediatric patients [90]. Also, the SARS-CoV-2 receptor ACE2 is highly 
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expressed on differentiated enterocytes suggesting that the intestine is a vital target 
organ for the pathogen. Therefore, models to understand the mechanism of SARS-
CoV-2 and validate drug efficiency in the gut for COVID-19 patients are the need of 
the hour.
Based on the high homology of SARS-CoV-2 to SARS-related coronaviruses iso-
lated from horseshoe bats, J. Zhou et al. established and characterized expandable 
intestinal organoids derived from Chinese horseshoe bats of the Rhinolophus sinicus 
species that can recapitulate bat intestinal epithelium [41]. These bat enteroids were 
readily infectable and could sustain SARS-CoV-2 replication. They also demon-
strated active replication of SARS-CoV-2 in human intestinal organoids along 
with isolation of infectious virus from the stool specimen of diarrheal COVID-19 
patients [91]. This again confirmed that the established culture conditions for 
human intestinal organoids could be extended to other members of the mammalian 
species.
This report, along with the work done by M. M. Lamers et al. [44] and R. Zang 
et al., unanimously reported that the intestine is a potential site of SARS- CoV-2 rep-
lication since enterocytes, the most common cell type of the intestinal epithelium, 
get readily infected [92]. M. M. Lamers et al. established human small intestinal 
organoids (hSIOs) from primary gut epithelial stem cells containing all prolifera-
tive and differentiated cell types of the in vivo epithelium [44]. Of note, hSIOs 
have been utilized for in vitro culturing of norovirus for the first time. The authors 
used confocal and electron microscopy to show that SARS-CoV and SARS-CoV-2 
infect enterocyte lineage cells in an hSIO model. They reported similar infection 
rates of enterocyte precursors and enterocytes, whereas ACE2 expression increased 
~1000-fold upon differentiation at the mRNA level. Therefore, while the infected 
enterocytes upregulated the viral response genes through cytoplasmic sensing of 
the viral RNA genome, the host-cell membrane-bound serine proteases TMPRSS2 
and TMPRSS4 were found to cleave the SARS- CoV-2 spike protein to facilitate 
viral entry. They conclude the following facts from this study: (a) intestinal epi-
thelium supports SARS-CoV-2 replication, (b) hSIOs serve as a faithful biological 
model for coronavirus infection, and (c) viral entry is supported even at low ACE2 
concentrations.
Since organotypic cultures are derived from pluripotent or organ restricted stem 
cells having the ability to mimic a natural 3D environment, they need a cell source 
with excellent self-renewal ability. The gut is one such source that allows unlimited 
replenishments of a particular cell type or tissue. Single-layered human intestinal 
organoids (HIOs) derived from human adult gut stem cells contain only epithelial 
cell types [93]. Pluripotent stem cells derived from HIOs (PSC-HIOs) made of 
endodermal/mesodermal progeny [94], resembling epithelium and fibroblasts or 
gut capillaries, respectively [95]. While PSC-HIOs are not 100% mature, HIOs are 
architecturally too simple, resulting in lower in vivo transplantability and analyti-
cal access to intermediate developmental stages. Until further modifications are 
done on them, both models are comparable and complementary to each other with 
model-specific pros and cons. As per previous reports, HIOs express ACE2 and are 
susceptible to SARS-CoV-2 [44, 92].
Inspired by the prior human intestinal organoids derived from pluripotent 
stem cells (PSC-HIOs) for modeling of gastrointestinal infections, J. Kruger et al. 
used this organoid model to dissect SARS-CoV-2 pathogenesis and then study its 
inhibition by remdesivir and famotidine (histamine-2-blocker), a potential drug 
candidate for COVID-19 treatment [96]. Immunostaining for ACE2 and TMPRSS2 
showed large expression in the gastrointestinal tract with maxima in the intestine. 
This ready infection of organoids with SARS-CoV-2 followed by the viral spread 
across entire PSC-HIOs subsequently led to organoid deterioration except goblet 
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cells lacking ACE2 expression. The drug testing data showed that remdesivir and 
EK1 (but not famotidine) effectively inhibited SARS-CoV-2 infection in a dose-
dependent manner at a low micromolar concentration which rescued the morphol-
ogy of PSC-HIOs. This is a benchmark study that has established the applicability 
of PSC-HIOs in the field of organ-specific drug testing related to gut infection, like 
SARS-CoV-2, rotavirus, norovirus, enterovirus 71, and human adenovirus.
3.4 Human capillary organoids
Since ACE2 is the SARS-Cov-2 receptor, clinical-grade human recombinant 
soluble ACE2 (hrsACE2) has already undergone clinical phase 1 and phase 2 testing. 
hrsACE2 slowed or even stopped the virus’s systemic dissemination from the lungs 
to other tissues, including potentially reducing SARS-CoV-2 attacks on the endo-
thelial cells of the blood vessel linings. hrsACE2 has shown promising therapeutic 
efficacy in treating severe COVID-19 [97]. To this end, V. Monteil et al. pursued 
the development of engineered human blood vessel organoids and human kidney 
organoids to get confirmatory evidence on the effect of hrsACE2 on SARS-CoV-2 
infection in multiple human organoid models [98].
To begin with, they first isolated the SARS-CoV-2 from a nasopharyngeal sample 
of a patient in Sweden with confirmed COVID-19, cultured it on Vero E6 cells, and 
successfully isolated the virus for characterization by next-generation sequencing 
and electron microscopy. The cellular studies showed that hrsACE2 can reduce viral 
growth in Vero E6 cells by a factor of 1,000–5,000. Their data demonstrated that 
hrsACE-2 can inhibit in vitro SARS-CoV-2 infection in a dose-dependent manner, 
unlike mouse rsACE2 highlighting the specificity of hsrACE2 in blocking SARS-
CoV-2 entry. With the in vitro evidence at hand, they moved on to the organoid 
model studies.
Before getting into the deeper details, let us have a look at the background 
for capillary organoid research in the light of SARS-CoV-2. It was already well-
known during that time that viremia initiates during the course of COVID-19 
despite the irregular observation of viral RNA in blood [88]. However, a viral size 
of 80–100 nm is suggestive of the fact that local tissue infections can only occur 
through the viremic invasion into vascular endothelial cells unless there is preexist-
ing tissue damage. This hypothesis was tested by infecting iPSC-derived human 
capillary organoids, which resemble human capillaries with clear lumen, lined 
by CD31+ endothelial cells and PDGFR+ pericyte cells and basal membrane [99]. 
A qRT-PCR analysis of these organoids for the presence of viral RNA indicates a 
gradual rise in the levels of viral RNA from day 3 to 6 of infection, proving active 
replication and production of progeny virus. This was followed by a marked 
decrease in replication without any associated toxicity on adding hrsACE2 to the 
capillary organoid culture.
SARS-CoV-2 can directly infect blood vessel cells which can also shed progeny 
viruses. Most importantly, this can be significantly inhibited by hrsACE2 at the 
early stages of the infection. This is the underlying rationale behind the hope of 
using soluble ACE2 for protecting the host body from lung injury and block the 
virus from entering target cells. Having said that, no data on its impact during the 
advanced stage of COVID-19 is currently accessible [98].
3.5 Kidney organoids
Since renal organotropism was becoming increasingly prominent in SARS-
CoV-2, M. Glatzel et al. did an in silico data analysis of single-cell RNA sequencing 
that was available in the public datasets. Their calculations revealed that RNA of 
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genes (ACE2, TMPRSS2, CTSL) that help to promote the viral infection is enriched 
in multiple kidney-cell types from fetal development through adulthood. This 
corroborates previous reports stating that enrichment may facilitate SARS-CoV-2–
associated kidney injury [77]. They also quantified the SARS-CoV-2 viral load in 
precisely defined kidney compartments obtained with the use of tissue microdis-
section from the samples of patients who underwent autopsy. The findings revealed 
that 50 percent of patients had observable SARS-CoV-2 viral loads in all kidney 
compartments tested, with glomerular cells being the most often infected [100].
V. Monteil et al. adapted their previously published procedure [97] to produce 
kidney organoids from human embryonic stem cells into 3D suspension culture 
to assess if SARS-CoV-2 would directly invade human tubular kidney cells [101]. 
Kidney organoids showed conspicuous tubular-like shapes, as observed by Lotus 
tetraglobus lectin (LTL), a standard marker of proximal tubular epithelial cells. 
Similar to their human capillary organoid study, infections of kidney organoids 
were monitored for at least six days post-infection, and their qRT-PCR data were 
analyzed for the presence of viral RNA. The team used Vero E6 cells to determine 
the virus’s progeny. SARS-CoV-2 reproduced in kidney organoids, as predicted in 
cells and tissues that express ACE2. The engineered kidney organoids developed 
infectious progeny virus, as shown by the ability of supernatant from infected 
kidney organoids to infect Vero E6 cells on day six post-infection. hrsACE2 signifi-
cantly decreased SARS-CoV-2 infections in a dose-dependent way in the human 
kidney organoids, with no evidence of toxicity. In summary, engineered human 
kidney organoids can also be infected with SARS-CoV-2, and this infection can be 
inhibited by hrsACE2, similar to blood vessel organoids.
Taken together, renal tropism explains the major clinical signs of kidney injury in 
patients with COVID-19 having mild or severe symptoms. These studies also predict 
that SARS-CoV-2 infection can potentially aggravate any preexisting renal conditions. 
The coronavirus receptor ACE2 is expressed in kidney organoids, which may help 
researchers further understand the disease’s systemic effects, and multiple questions 
regarding the pathogenesis can be answered. Thus, the development of multi-organ 
organoids can address the multi-organ dysfunction, a symptom of COVID-19 illness.
4. Future directions and conclusion
After SARS-CoV and MERS-CoV, SARS-CoV-2 is the third coronavirus in terms 
of pathogenicity to jump to humans within two decades. This suggests that similar 
zoonotic coronavirus spillovers can happen again in the near future. Nevertheless, 
the events relating to coronavirus pathogenesis and transmission are not completely 
known yet. There is a lack of efficient in vitro systems to accurately model host 
tissues. As conventional animal models, like mice, are not natural hosts to SARS-
CoV-2 infection, there is a surge in the development of alternate pre-clinical models 
to recapitulate the targeted human organs.
Herein, organoid technology used to model human organ development and vari-
ous human pathologies in a petri dish has played a significant role in understanding 
SARS-CoV-2 infection and replication. For drug response studies, drug screening, 
and repurposing, organoids, especially patient-derived organoids, have become 
popular. Organoid-based studies are leading to personalizing drugs, formulating 
regenerative medicine, and establishing gene therapy. In comparison to age-old 
animal models and cell lines, there has been a noticeable improvement in the repro-
ducibility of results and statistical power of experiments. From all previous data, 
human organoids of lung, gut, kidney, brain, and blood vessels represent excellent 
experimental models to study the biology of SARS-CoV-2 [44].
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Having said that, researchers working in this field are still trying to identify 
and troubleshoot the inherent challenges in various aspects of handling organoids, 
including the maintenance costs, cross-technique artifacts, and interpretation 
of data [26]. It is now well known that the generation and handling of organoids 
are way more tedious than two-dimensional cell culture protocols. Moreover, the 
essential growth factors being more expensive and not explicitly tested for applica-
tions in the organoid system, one has to prepare them in-house. With the emergence 
of various commercial sources for reagents tailored to the organoid culture, there 
is reason to believe that this problem will be fixed quickly. Moreover, the range of 
cellular heterogeneity for a particular organoid system needs to be improved. Also, 
mimicking the native micro-and matrix-environment encountered by cells within 
organoids remains a challenge. Reverse engineering methodologies are only in their 
infancy as it comes to developing rigorous protocols for the in vitro maturation of 
organoids that are largely fetal-like in cultures [102]. Advances in stem cell, progen-
itor cell, and pluripotent stem cell handling and directed differentiation techniques 
will soon help create more physiologically relevant organoids.
In combination with genome editing techniques for manipulating 3D models, 
organoid technology will be implemented at a large scale in basic and clinical 
research in the forthcoming era [14]. Progress with other technologies, such 
as microRNA switches and potentially CRISPR–Cas9, 3D bioprinting, and 3D 
organoids, will further advance the fast-developing multi-organ disease modeling 
COVID-19 and its associated therapeutic build-up. Though organoid technol-
ogy suffers from multiple lacunae but COVID-19 has shown the feasibility and 
practicality of the organoid platform, suggesting further investment to create an 
in vitro organ mimicking reliable system for successful and effective discovery of 
therapeutics.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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